Clinical trial
Sputum-derived Cellular Targets After Xolair (Omalizumab)
NCT02658877
Study timeline
Study start (unknown)2016-01-01Date precision: month
Registry last updated2019-09-30
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Asthmaunresolved
Interventions
OmalizumabDRUG · verified · RxNorm: omalizumab
PlaceboDRUG
Sponsors & collaborators
NYU Langone Healthlead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02658877 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.